Загрузка...
Liraglutide suppression of caloric intake competes with the intake-promoting effects of a palatable cafeteria diet, but does not impact food or macronutrient selection
Liraglutide, a Glucagon-Like Peptide 1 (GLP-1) receptor agonist, is used as a treatment for Type 2 Diabetes Mellitus and obesity because it improves glycemia and decreases food intake. Here, we tested whether chronic activation of the GLP-1 receptor system with liraglutide would induce decreases in...
Сохранить в:
| Опубликовано в: : | Physiol Behav |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5545097/ https://ncbi.nlm.nih.gov/pubmed/28366815 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.physbeh.2017.03.045 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|